Comparative Pharmacology
Head-to-head clinical analysis: CALCIPARINE versus HEPARIN SODIUM 12 500 UNITS IN DEXTROSE 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CALCIPARINE versus HEPARIN SODIUM 12 500 UNITS IN DEXTROSE 5 IN PLASTIC CONTAINER.
CALCIPARINE vs HEPARIN SODIUM 12,500 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Unfractionated heparin (UFH) potentiates antithrombin III (ATIII) activity, leading to inhibition of factor Xa and thrombin (factor IIa). It also binds to heparin cofactor II, inhibits platelet aggregation, and increases vascular permeability.
Heparin binds to antithrombin III (ATIII) and accelerates its inhibition of thrombin (factor IIa) and other serine proteases (factors Xa, IXa, XIa, XIIa) in the coagulation cascade, thereby preventing fibrin clot formation.
5000 IU subcutaneously twice daily for prophylaxis; 5000 IU intravenous bolus followed by 800-1000 IU/hour continuous intravenous infusion for treatment.
Continuous IV infusion: Initial bolus 80 units/kg, then 18 units/kg/hour; subsequent dose adjusted based on aPTT. Typical infusion rate: 20,000–40,000 units/24 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5 hours (subcutaneous) after a 5000 IU dose. With therapeutic doses (e.g., 15,000 IU/24h), half-life may prolong to 2-3 hours. Clinical context: Half-life is dose-dependent and increases with heparin clearance saturation.
Terminal elimination half-life is 1-2 hours at therapeutic doses, dose-dependent: 30-60 min after IV bolus of 25 U/kg, increasing to 1.5-2.5 hours after 400 U/kg. Prolonged in hepatic/renal impairment and pulmonary embolism. Clinical context: continuous infusion achieves steady-state after ~4-6 hours.
Primarily renal, with 40-60% of the dose excreted unchanged in urine. Minor biliary/fecal elimination (<10%).
Heparin is eliminated primarily via hepatic metabolism and renal excretion. Approximately 50% of a dose undergoes hepatic desulfation and depolymerization to form uroheparin, which is excreted in urine. Unchanged heparin is cleared renally via saturable, dose-dependent mechanisms. Biliary/fecal elimination is negligible (<5%).
Category C
Category A/B
Anticoagulant
Anticoagulant